Abstract: Methods of generating an autologous cellular vaccine comprising monocytes or neutrophils and an antigenic polypeptide or nucleotide encoding the antigenic polypeptide are provided. The antigen-loaded cell-based vaccine compositions made using these methods are also provided. Methods of using the antigen-loaded cell-based vaccine compositions are also provided and these vaccines may be used to treat cancer. Kits for carrying out the methods described herein are also provided.

Abstract: The presently disclosed subject matter is directed to compositions and methods for treating CaMKK2-mediated ophthalmic diseases, including but not limited to 1) ocular surface inflammatory diseases (OSIDs), including but not limited to ocular graft versus host disease, ocular cicatricial pemphigoid, vernal keratoconjunctivitis, allergic eye disease, meibomian gland dysfunction, aqueous tear deficiency (common dry eye disease), corneal scarring, and conjunctival scarring and fibrosis; 2) uveitis and other inflammatory diseases of the eye, including but not limited to keratitis, scleritis, iritis, iridocyclitis, intermediate uveitis, pars planitis, posterior uveitis, choroiditis, chorioretinitis, retinitis, or panuveitis of noninfectious, infectious, or idiopathic etiologies; and 3) “back of the eye” retinal diseases, which include dry age-related macular degeneration, neovascular age-related macular degeneration, diabetic retinopathy, retinal vascular diseases (e.g.

Abstract: Disclosed herein are CRISPR/Cas9-based gene activation systems that include a fusion protein of a Cas9 protein and a protein having histone acetyltransferase activity, and methods of using said systems.

Abstract: Disclosed herein are compositions of transcription activator-like effectors transcription factors and methods of using the compositions for inducing gene expression of mammalian genes.

Abstract: Disclosed herein are therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use.

Abstract: Disclosed herein are therapeutic applications of CRISPR/Cpf1-based genome editing.

Abstract: Exemplary layered double hydroxides (LDHs) may comprise a compound of formula Mg4-yAlXy(OH)2, wherein X is Mn+2, Cu+2, Zn+2, or Fe+2, and 0.01?y?1. Exemplary layered double hydroxide hydrogels (LDH-gels) may comprise a hydrogel and at least one LDH. Exemplary hydrogels may comprise polyethylene (glycol) diacrylate (PEGDA) or polyacrylamide (PAAm). Exemplary LDH-gels may comprise at least one LDH comprising a compound of formula Mg4-yAlXy(OH)2, wherein X is Mn+2, Cu+2, Zn+2, or Fe+2, and 0.01?y?1.

Abstract: The present disclosure describes, in part, compositions and methods for safeguarding plant immunity to pathogens in response to environmental changes.

Abstract: A motion planner of a computer system of a primary agent, e.g., an autonomous vehicle, uses reconfigurable collision detection architecture hardware to perform a collision assessment on a planning graph for the primary agent prior to execution of a motion plan. For edges on the planning graph, which represent transitions in states of the primary agent, the system sets a probability of collision with another agent, e.g., a dynamic object, in the environment based at least in part on the collision assessment. Depending on whether the goal of the primary agent is to avoid or collide with a particular dynamic object in the environment, the system then performs an optimization to identify a path in the resulting planning graph with either a relatively low or relatively high potential of a collision with the particular dynamic object. The system then causes the actuator system of the primary agent to implement a motion plan with the applicable identified path based at least in part on the optimization.

Abstract: The present disclosure describes systems and methods for wastewater treatment. In some embodiments, a system may include one or more of a pair of electrodes, a first membrane selectively permeable to a first wastewater nutrient, a second membrane selectively permeable to a second wastewater nutrient, and at least one spacing frame comprising a structural element, a gasket, and a flow channel. In some embodiments, the system may further include a septic tank.

Abstract: Multifunctional microelectronics fiber probes can be chronically implanted in tissue of awake-behaving animals for understanding brain-viscera communication. These fiber probes can be made using thermal drawing to make hundreds of meters of flexible fiber that incorporates features such as light sources, electrodes, thermal sensors, and microfluidic channels in a multilayered configuration. The fiber mechanics can be tuned for two distinct device layouts: (1) higher-modulus, flexible brain fibers for implantation into deep-brain; and (2) soft, compliant gut fibers for implantation into the small intestine. Brain fibers can modulate the deep-brain mesolimbic reward pathway. Gut fibers can perform peripheral optogenetic stimulation of vagal afferents from the intestine to stimulate brain reward neurons.

Abstract: The present disclosure provides, in part, modulators of prostate-specific G-protein receptor (OR51E2/PSGR) and methods of treating, preventing, and diagnosing prostate cancer using the same.

Abstract: Methods for treating and preventing pain are described. The methods include administering a therapeutically effective amount of a GPR37L1 ligand to a subject in need thereof. Also described herein are pharmaceutical compositions containing the GPR37L1 ligands.

Abstract: The present disclosure describes methods and systems for risk detection and intervention for neurodevelopmental disorders. The method includes assessment of risk level, guidance and treatment recommendations and strategies, and longitudinal monitoring of patients with neurodevelopmental disorders. The assessments and monitoring can be integrated into the patient's health care program and electronic health record (EHR).

Abstract: A method comprising effecting a change in a shape of a droplet, wherein the droplet is disposed over a substrate in sensing proximity to a sensor and the droplet has a starting surface area exposed to the sensor; and producing an expanded surface area of the droplet in the sensing proximity exposed to the sensor, wherein the expanded surface area exposed to the sensor is greater than the starting surface area exposed to the sensor.

Abstract: The invention is directed to bispecific molecules comprising an HIV-1 envelope targeting arm and an arm targeting an effector cell, compositions comprising these bispecific molecule and methods of use. In certain aspects, the bispecific molecules of the present invention can bind to two different targets or epitopes on two different cells within the first epitope is expressed on a different cell type than the second epitope, such that the bispecific molecules can bring the two cells together. In certain aspects, the bispecific molecules of the present invention can bind to two different cells, wherein the bispecific molecules comprises an arm with the binding specificity of A32, 7B2, CH27, CH28 or CH44.

Abstract: A system and method are provided for creating magnetic resonance (MR) images with reduced motion artifacts from the MR data from which the images are produced. The method includes selecting a candidate image from a plurality of candidate images reconstructed from the MR data. The method also includes registering the candidate image to a reference image, comparing the candidate image to a consistency map, and, based on comparing the candidate image using the consistency map, selecting a blending algorithm. The method also includes generating a blended image using the blending algorithm and the candidate image and repeating these steps for each candidate image. The method also includes performing a Fourier aggregation to generate a combined image and displaying the combined image with reduced motion artifacts compared to the plurality of candidate images.

Abstract: The present disclosure is directed to methods of treating a steatosis- associated disorder by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage.

Abstract: Plasmonics-active nanoprobes are provided for detection of target biomolecules including nucleic acids, proteins, and small molecules. The nucleic acids that can be detected include RNA, DNA, mRNA, microRNA, and small nucleotide polymorphisms (SNPs). The nanoproprobes can be used in vito in sensitive detection methods for diagnosis of diseases and disorders including cancer. Multiplexing can be performed using the nanoprobes such that multiple targets can be detected simultaneously in a single sample. The methods of use of the nanoprobes include detection by a visible color change. The nanoprobes can be used in vivo for treatment of undesireable cells in a subject.

Abstract: Systems and methods for multi-modal imaging using an endoscope having an instrument channel, where the imaging is achieved without using the channel, are disclosed. The systems can include a multi-modal imaging paddle housing couple to a distal end of the endoscope. The housing can receive at least two imaging probes. The imaging probes can be an angle-resolved low-coherence interferometry probe (a/LCI) and an optical coherence tomography (OCT) probe. The housing can be scaled and positioned to be visible via the endoscope camera. The system and method can include locating the housing in a region of interest using the endoscope camera, acquiring OCT measurements to identify targets, and then acquiring a/LCI measurements at the identified targets.